Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We will enter the Nasdaq this year through a reverse into an already listed company. We may be waiting for a deal to be signed for Polb 001 firstly so we bring more to the table. Hopefully it will be a company which has revenue generating products in toe already and finds our package a good fit with their own. We already have a Nasdaq listed company carrying out trials in a few months on our oral encapsulation Ano Bio collaborative project. It may be a license that they want in their stable and enough to make them ambitious to join forces with our company and it's very impressive team. This year will be our pivot to success.
Mary you talk nonsense, if you set a figure you probably would have sold...who cares what you are doing and your day trading strategy, it not relevant to investors on this board is it? Go ramp somewhere else instead.
I'm a little late to the party here Mary only a few days in but I reckon there will be a pump on the next news and it may hit 12 before that.
Resetting my trim to higher soon be in the 12/14p range.
Nice find eirico, but will need to get the share price up unless you are happy with a 40:1 reduction to meet Nasdac minimum. I'm not. I'm not sure it would generate much interest with a couple of phase 1 trials under the belt. Let's bed down the £15+ million needed for the phase 2 and to keep the ship afloat and grow the pipeline for the next couple of years whilst that happens and then if success it will fly.
Veteran private investors concur that the allure of the Alternative Investment Market (AIM) is waning. Emerging enterprises and startups encounter heightened challenges in securing operational funds, often resorting to less favourable financial instruments like death spiral convertible bonds. Furthermore, the escalating regulatory framework within the European Union dissuades investors from engaging with the life sciences sector, posing a potential threat to innovation across Europe, including Ireland. This sentiment was echoed by Michael Lohan, the Chief Executive of IDA Ireland, the agency responsible for attracting foreign direct investments. In his conversation with the Financial Times, Lohan highlighted concerns that recent legislative proposals from Brussels targeting the pharmaceutical industry could exacerbate the technological divide between the United States and the European Union. This regulatory environment contributes to my belief that companies such as @PoolbegPharma, #POLB Pharma, & @hVIVO_UK #HVO must be contemplating listings in the U.S. market where valuation and conditions are much more favourable. The latter, in particular, seems increasingly probable as the company continues to expand its revenue base, enhance profitability, and solidify its position as a leading Contract Research Organization (CRO).
https://twitter.com/LEMMINGINVESTOR/status/1775632413571359033
https://www.irishtimes.com/business/2024/04/03/eu-rules-drive-pharma-backers-to-the-us-says-ida-ireland-chief/#:~:text=Michael%20Lohan%2C%20chief%20executive%20of,comes%20to%20cutting%2Dedge%20technologies
No way in hell I'm buying into an IPO in the current market. Will be 30% down within a month im betting
EGT, which lists Dublin as its principle place of doing business, would have a market capitalisation of close to an initial £15 million by the time it starts trading on London’s AIM junior stock market on April 8th. Mr Friel’s stake will be diluted to about 19 per cent from almost 44 per cent as a result of the fundraising, still leaving him as the largest shareholder.
Slightly off topic, CF's new business venture, has anyone managed to buy into this IPO or awaiting 8th April?
European Green Transition intends to invest in a portfolio of green economy assets in Europe. These include critical materials projects, solar and wind farms, and rehabilitation and processing projects. It has a launch portfolio of assets, including the Olserum rare earth element project in Sweden.
European Green Transition (EGT), a company cofounded by serial entrepreneur Cathal Friel focused on assets and businesses needed for the green energy transition, has raised an initial £6.45 million (€7.6m) from professional investors in its initial public offering (IPO) in London.
The company has now opened the offer to small retail investors with the aim of raising as much as £500,000 of further equity by midday on April 4th, it said in a statement on Thursday.
Go Baby Go.
As they say you wouldn't get a team of such quality joining Poolbeg unless they saw massive potential.
New products with cash generation will shortly be brought in by Dave Allmond and collectively with that our other projects moving forward and a partnership deal signed for 001 will knock the lids off this. Revenue at this stage is key. We are in execution mode at the moment with news incoming any day.
I would say that CF is actively working on a reverse into Nasdaq which could bring in revenue generating products for us. Will we suffer dilution when this happens remains to be seen.
At the 37-minute mark, Paul Hill and John Hughman discuss HVO for about 5 minutes, and at 46mins POLB is discussed.
Great update.
https://www.youtube.com/watch?v=lDgZmvy6pdQ
It has been stated by JS that we have two different Pharmas interested in Polb 001 with one of them wanting to trial it later in the year in relation to Car-T treatment to combat the resulting Cytokine storm.
Surely this will result in a deal signed of some sort for exclusive partnership which is what Poolbeg Pharma want rather than in license to multiple parties. If it is an exclusive partnership the second party would if interested be under pressure to make their mind up if they want a slice of the cake.bThe structure of this deal is all guesswork to us stakeholders at the moment but it has been hinted that the preferred deal would be a single one covering all applications. We are adding different uses in order to make the partnership more valuable and more attractive for those nibbling at the hook.
I'm not sure how much new information we are really going to get from the annual results. An update on cash/burn rate etc, even that we can't really forecast going forward as we have little idea what the new Management team costs are, but apart from that, any update will be forward focused as there's no real revenue to speak about. The key information update is what's coming with POLB-001 partnership discussions and how close we are to agreement. Hopefully we are very close to a major deal to catapult the SP to multiples of the current price...
Didn't realise LSE is closed until Tuesday so I guess we will wait until then for annual results, happy Easter all,enjoy.
Buy sub 9 / 9.2,in the build phase.
Silverhorse, how's the Polb day trading going? You change your stance more than a Liberal Democrat MP.
Good end of the day backs to double digits on the ask. We could well get end of year results tomorrow if last year is anything to go by. It would be nice to get a cherry on top with the results. We shall see.
Results are a bit late, i feel no news middle of april, it will likely slip back to 9p on small sells so let it happen
MaryB, is your crystal 🔮 ball telling you to buy or sell today? 🤔
Not interested in anything that TW^T has to say, I think MaryB talks more sense using a crystal 🔮 ball, lol 😆
No sign of the TW podcast yet from the other day.
No,crystal ball, just observation and risk management.
Within the spread, sub 9 works, 9/9.2 can get 9.08, 9/9.3 can get 9.21 etc. Never tempted to buy above 11p, a trim atm. Trim over 11 unreleased news propelling.
That's how I roll here, not a recommendation.
Still see this as a trebler so aiming for 800k shares at 6p average and then phase 2 is reduce that position sub zero by a sell above 12p.
🔮
Well done, but if everyone did that they would be no buyers at the top and no sellers at the bottom. Does your crystal 🔮 ball give the sell price and the buy price on a daily basis?